Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor. Taribavirin is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor. Taribavirin is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia. |
In vitro | Taribavirin (0-2 μM; 24 hours) obviously induces MCF-7 cell death. It recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells [1]. |
Molecular Weight | 243.22 |
Formula | C8H13N5O4 |
CAS No. | 119567-79-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Taribavirin 119567-79-2 Others inhibitor inhibit